
    
      The phase I part of the study will enroll patients with advanced or metastatic solid tumors
      who have failed at least one previous treatment. The purpose of the phase I part is to assess
      the safety of the investigational treatment and select the recommended phase II dose-regimen.
      The phase II part of the study will enroll patients with advanced or metastatic HER2-negative
      breast cancer who have not received treatment for their metastatic disease. The purpose of
      the phase II part of the study is to assess safety and efficacy of the investigational
      treatment in breast cancer. The study doctor will determine what phase patients will be
      enrolled in.
    
  